Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TPST-1120

Small molecule · developed by Tempest Therapeutics

Phase 1 Most advanced trial (none active)
TPST Developer
1 Registered trials

What is TPST-1120?

TPST-1120 is an orally administered agent given twice daily, studied in multiple advanced solid tumors including hepatocellular carcinoma, prostate, renal cell, lung, colorectal, head and neck, breast, urothelial, biliary, gastroesophageal, pancreatic cancers and sarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Oncology
Developer
Tempest Therapeutics (TPST)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03829436 Phase 1 Hepatocellular Carcinoma Completed TPST

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CholangiocarcinomaColorectal CancerGastroEsophageal CancerHepatocellular CarcinomaMetastatic Castration Resistant Prostate CancerNon-small Cell Lung CancerPancreatic CancerRenal Cell CarcinomaSarcomaSquamous Cell Carcinoma of Head and NeckTriple-Negative Breast CancerUrothelial Carcinoma

More from Tempest Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TPST page.

Follow TPST, the company behind TPST-1120

See TPST's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TPST catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.